
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Santa Monica, Calif. - While genetics might be a strong factor in the development of melanoma, studies show that sun exposure is a key component.